Brief: Pfizer And Astellas’ Padcev Plus Keytruda Shows Long-Term Efficacy In First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer
10/02/2025 22:31
Feb 10 (Reuters) - Astellas Pharma Inc 4503.T :
* PFIZER AND ASTELLAS’ PADCEV® (ENFORTUMAB VEDOTIN-EJFV)
PLUS
KEYTRUDA® (PEMBROLIZUMAB) SHOWS LONG-TERM EFFICACY IN FIRST-LINE
TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
(LA/MUC)
* ASTELLAS PHARMA INC: NO NEW SAFETY SIGNALS IDENTIFIED FROM
PHASE
3 EV-302 TRIAL
* ASTELLAS PHARMA INC: ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB
CONTINUES TO DEMONSTRATE SUPERIOR EFFICACY VERSUS CHEMOTHERAPY
IN BROAD POPULATION
Source text: ID:nBwbjwWb8a
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)